99% Raw Material Levonorgestrel CAS 797-63-7 Pharmaceutical Powder Levonorgestrel

Name: 99% Raw Material Levonorgestrel CAS 797-63-7 Pharmaceutical Powder Levonorgestrel
Brand: Beijing Mesochem Technology Co., Ltd.
SKU: 917048245

Beijing, ChinaBeijing Mesochem Technology Co., Ltd.

US$10.00-100.00

1 g

Sample price:US$100.00/g.Request sample

Product profile

Customization

Available

Function

Antineoplastic, Chemical Medicine Raw Materal

Certification

GMP, USP, Ep, Bp

Model NO.

797-63-7

Grade Standard

Medicine Grade

Type

Chemical Medicine Raw Materal

State

Powder

Volatile

Not Volatile

Name

Levonorgestrel

CAS Registry Number

797-63-7

Molecular Formula

C16h17n7o2s

Molecular Weight

371.42

Transport Package

25kg/Barrel

Specification

GMP

Trademark

Mesochem

Origin

China

HS Code

2934999090

Production Capacity

G/Kg

Company profile

Beijing Mesochem Technology Co., Ltd.

Beijing, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2010-04-01 CertifiedNearest Port: Tianjin PortAverage Response Time: ≤4.68h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryBeijing Mesochem Technology Co., Ltd. is a China-based limited company established in 2009, with 35 employees and reported operations in health, medicine, and chemicals. The supplied information describes two production bases with approximately 67,000 m² of production area and 30,000 L of manufacturing equipment, while another record lists an 800 m² manufacturing plant; this discrepancy should be verified. The supplier reports more than 10 production lines, 6–10 quality-control staff, R&D, pilot, and commercial production capabilities, and product capacity information for several pharmaceutical compounds. It holds ISO 9001:2015 certification and states that its quality system is aligned with FDA, ICH, and EDQM requirements, although FDA review status is not equivalent to approval. Export sales account for 71%–90% of total sales, and three individual trade records identify Everest Pharmaceuticals Limited as a buyer in Bangladesh. Evidence is insufficient to assess after-sales service, customization, and...

Supplier typeThe supplier is identified as a China-based limited company with a combined business-entity type, while one record classifies its company nature as a trading company. Its stated commercial areas include health and medicine and chemicals, and it also reports production bases and manufacturing capabilities, indicating a mixed trading and manufacturing profile.

CertificationsThe supplier reports holding an ISO 9001:2015 certificate and states that its quality assurance system is established to meet FDA, ICH, and EDQM requirements. The slices do not provide certificate scope, validity dates, or evidence of FDA approval, but the stated ISO certification is explicit.

R&D capabilityThe supplier states that it has R&D, pilot-production, and commercial-production capabilities, and reports two ANDAs under FDA review, with more than ten formulations submitted for marketing authorization in multiple regulatory markets. Three R&D engineers are reported, supporting demonstrated development activity, although the depth and success of the innovation program are not fully documented.

Production capacityThe supplier reports two production bases, approximately 67,000 m² of production area, about 30,000 L of equipment, more than 10 production lines, and 6–10 quality-control staff. It also provides product-specific annual productivity entries for adapalene, pimavanserin tartrate, tenofovir alafenamide fumarate, tofacitinib citrate, and lorcaserin hydrochloride. However, the separate 800 m² plant-area record conflicts with the 67,000 m² figure and requires verification.

Client casesThree trade records identify Everest Pharmaceuticals Limited as a buyer for finerenone, velpatasvir, and olaparib, each associated with Bangladesh and one recorded transaction. These records provide concrete customer and product examples, but the limited transaction count does not demonstrate a broad or long-term customer portfolio.